Norofol 10mg/ml Emulsion for Injection for Cats and Dogs

Main information

  • Trade name:
  • Norofol 10mg/ml Emulsion for Injection for Cats and Dogs
  • Pharmaceutical form:
  • Emulsion for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Norofol 10mg/ml Emulsion for Injection for Cats and Dogs
    Austria
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • propofol
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0371/001
  • Authorization date:
  • 29-09-2010
  • EU code:
  • UK/V/0371/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:February2011

AN:01771/2009

SUMMARYOFPRODUCTCHARACTERISTICS

1. NameoftheVeterinaryMedicinalProduct

Norofol10mg/mlEmulsionforInjectionforcatsanddogs(UK,BG,CZ,LT,RO,SI,SK)

Vetofol10mg/mlEmulsionforInjectionforcatsanddogs(AT,CY,EE,FI,DE,EL,LV,

PT,ES)

2. QualitativeandQuantitativeComposition

Eachmlcontains:

ActiveSubstance

Propofol 10.0mg

Excipients

Forafulllistofexcipients,seesection6.1

3. PharmaceuticalForm

Emulsionforinjection.

Awhitehomogeneousemulsionwithnoappearanceofvisibledropletsorextraneous

foreignparticles.

4. ClinicalParticulars

4.1 TargetSpecies:

Dogsandcats.

4.2 IndicationsforUse,SpecifyingtheTargetSpecies:

NorofolInjectionisindicatedforuseindogsandcatsasashort-acting,intravenous

generalanaestheticforproceduresofshortduration,lastingupto5minutes;forthe

inductionandmaintenanceofgeneralanaesthesiausingincrementaldosestoeffect;

fortheinductionofgeneralanaesthesiawheremaintenanceisprovidedbyinhalation

anaesthetics.

4.3 Contraindications:

Donotuseinanimalsthatarehypersensitivetotheactivesubstanceoranyofthe

excipients.

Revised:February2011

AN:01771/2009

4.4 SpecialWarningsforEachTargetSpecies:

IfNorofolInjectionisinjectedveryslowly,aninadequateplaneofanaesthesiacan

occur.

Shakethevialgentlybutthoroughlybeforeopening.Donotuseifevidenceofphase

separationremainsaftergentleshaking.

4.5 SpecialPrecautionsforUse:

(i)SpecialPrecautionsforUseinAnimals

Duringinductionofanaesthesia,mildhypotensionandtransientapnoea,similarto

effectswithotherintravenousanaestheticagentsmayoccur.

Iftheproductisinjectedtoorapidly,cardiopulmonarydepressionmayoccur(apnoea,

bradycardia,hypotension).

WhenusingNorofolInjection,facilitiesforthemaintenanceofapatentairway,artificial

ventilationandoxygenenrichmentshouldbeavailable.

Inadvertentperivascularadministrationrarelycauseslocaltissuereactions.

Aswithotherintravenousanaestheticagents,cautionshouldbeexercisedindogsand

catswithcardiac,respiratory,renalorhepaticimpairment,orinhypovolaemicor

debilitatedanimals.

Sighthoundsmayhaveaslightlylongerdurationofrecoveryfromanaethesia

comparedtootherbreedsofdog.

(ii)Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Thisisapotentdrug:particularcareshouldbetakentoavoidaccidentalself-

administration.Aguardedneedleshouldpreferablybeuseduntilthemomentof

injection.

Washoffsplashesfromtheskinandeyesimmediately.

Intheeventofaccidentalself-administration,seekurgentmedicalattentionandshow

thelabeltothedoctor.AdvicetoDoctor:Donotleavethepatientunattended.

Maintainairwaysandgivesymptomaticandsupportivetreatment.

(iii)OtherPrecautions

None.

Revised:February2011

AN:01771/2009

4.6 Adversereactions(FrequencyandSeriousness):

Sideeffectsduringinduction,maintenanceandrecoveryareuncommon.Inductionis

generallysmooth,minimalevidenceofexcitationhasbeenobservedinasmall

proportionofanimals.Duringtherecoveryphase,vomitingandevidenceofexcitation

havebeenobservedinasmallproportionofanimals.

Inclinicaltrialsincats,transientapnoeaduringinductionandpaw/facelicking

characteristicsduringrecoveryhavebeenobservedinasmallproportionofanimals.

Inclinicaltrialsindogs,transientapnoeaduringinductionandmaintenancehavebeen

observed.

Ifpantingisevidentbeforeinduction,itmaycontinuethroughoutthesubsequent

periodsofanaesthesiaandrecovery.

4.7 UseDuringPregnancy,LactationorLay:

Propofolhasnotbeenusedindogsandcatswherethepregnancyistobemaintained,

buthasbeenusedsuccessfullyforinductionpriortoCaesareansectioninbitches.

4.8 InteractionwithotherMedicinalProductsandOtherFormsofInteraction:

Propofolhasbeenusedinassociationwithcommonlyusedpremedicantse.g.

atropine,acepromazine,diazepam;inhalationalagentse.g.halothane,nitrousoxide,

enfluraneandanalgesicagentse.g.pethidine,buprenorphine.Nopharmacological

interactionshavebeenencountered.

Theemulsionshouldnotbemixedwithothertherapeuticagentsorinfusionfluidsprior

toadministration.

Revised:February2011

AN:01771/2009

4.9 AmountstobeAdministeredandAdministrationRoute:

Theproductisindicatedforintravenousadministrationtodogsandcats.Thevial

shouldbeshakenthoroughlybeforeopening.

Induction:Theinductiondoseiscalculatedaccordingtobodyweightandmaybe

administeredtoeffectoveraperiodof10to40seconds.Alternatively,thecalculated

dosemaybegiveninfullasasinglebolustoeffect,atthediscretionoftheVeterinary

Surgeon(Seesection4.5i).Theinductiondoseisreducedbytheuseof

premedicants.

Thefollowingdoseratesareforguidanceandinpracticethedoserateshouldbe

basedonresponse.

Theaverageinductiondosefordogsandcats,eitherunpremedicatedorwhen

premedicatedwithatranquillisersuchasacepromazine,isasfollows:

Dose(mg/kgbodyweight) Dosevolume(ml/kg

bodyweight)

Dogs

Unpremedicated 6.5 0.65ml/kg

Premedicated 4.0 0.4ml/kg

Cats

Unpremedicated 8.0 0.8ml/kg

Premedicated 6.0 0.6ml/kg

Maintenance:Whereanaesthesiaismaintainedbyincrementalinjections,thedose

ratewillvarybetweenanimals.Incrementaldosesshouldbegiventoeffect.Dosesof

approximately1.25 –2.5mg(0.125–0.25ml)perkgbodyweightsustainanaesthesia

forperiodsofupto5minutes.

Maintenancebyinhalationagents:Whereinhalationagentsareusedtomaintain

generalanaesthesia,clinicalexperienceindicatesthattheremaybeaneedtousea

higherinitialconcentrationofinhalationagentthanisnormallythecasefollowing

inductionwithbarbiturateagentssuchasthiopentone.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary:

Accidentaloverdosageislikelytocausecardio-respiratorydepression.Respiratory

depressionshouldbetreatedbyartificialventilationwithoxygen.Cardiovascular

depressionrequirestheuseofplasmaexpandersandpressoragents.

4.11WithdrawalPeriod(s):

Notapplicable.

5. PharmacologicalProperties

Pharmacotherapeuticgroup:Anesthetics.

ATCVetCode:QN01AX10

Revised:February2011

AN:01771/2009

5.1 Pharmacodynamicproperties:

Propofol(2,6di-isopropylphenol,Diprivan;ICI35868)isanonbarbituratesubstituted

isopropylphenolwhichisusedfortheinductionandmaintenanceofanesthesia.

Propofolisashort-acting,intravenousgeneralanaestheticforproceduresofshort

duration,lastingupto5minutes.Recoveryfromanaesthesiaisusuallyrapid.

5.2 Pharmacokineticproperties:

Afterasinglebolusdose,bloodlevelprofilesarecharacterisedbyarapiddistribution

phaseandarapideliminationphase.Noaccumulationofbloodlevelshasbeen

observedaftermultipledailydosing.Urinaryexcretionisthemajorrouteofelimination

ofmetabolitesfromthebody.

AfterintravenousadministrationofNorofol10mg/mlEmulsionforInjectiontodogsata

doserateof6.5mgpropofolperkgbodyweightononeoccasion,thefollowing

parameterswereobserved:Volumeofdistributionof0.938

0.0896L/kg,T½(alpha)

1.61

0.239minutesandT½(beta)29.5

7.06minutes.

6. PharmaceuticalParticulars

6.1 ListofExcipient(s):

Lecithin

Glycerol

RefinedSoybeanOil

SodiumHydroxide

WaterforInjections

6.2 Incompatibilities:

NorofolInjectionshouldnotbemixedwithotherproducts.

6.3 Shelf-Life:

2years.

Withdrawnproductshouldbeusedimmediately.Thisproductdoesnotcontainan

antimicrobialpreservative.Anysolutionremaininginthevialfollowingwithdrawalofthe

requireddoseshouldbediscarded.

6.4 SpecialPrecautionsforStorage:

Donotstoreabove25°C.

Donotfreeze.

Protectfromlight.

Keepthecontainerintheoutercarton.

Storevialsintheuprightposition.

Revised:February2011

AN:01771/2009

6.5 NatureandCompositionofImmediatePackaging:

NorofolInjectionispresentedin20mland50mltypeIclearglassvialssealedwith

bromobutylbungsandaluminiumcaps.

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinaryMedicinalProductsor

WasteMaterialsDerivedFromtheUseofSuchProducts,ifappropriate:

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements

7. MARKETINGAUTHORISATIONHOLDER

NorbrookLaboratoriesLimited

StationWorks

CamloughRoad

Newry

Co.Down,BT356JP

NorthernIreland

8. MARKETINGAUTHORISATIONNUMBER

Vm02000/4275

9. DATEOFFIRSTAUTHORISATION

9January2009

10. DATEOFREVISIONOFTHETEXT

February2011

5-12-2018

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily recalling 933 packages of Cow Pie fresh frozen meats for dogs and cats, produced in August 2017, because it has the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

7-6-2018

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Heartworm disease can be fatal to pets, but it is also preventable. Learn more about the dangers of heartworm disease and the importance of year-round prevention.

FDA - U.S. Food and Drug Administration